AU714694B2 - Creación de Inventos y Patentes con Inteligencia Artificial

AU714694B2 – Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids
– Google Patents

AU714694B2 – Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids
– Google Patents
Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids

Download PDF
Info

Publication number
AU714694B2

AU714694B2
AU34163/97A
AU3416397A
AU714694B2
AU 714694 B2
AU714694 B2
AU 714694B2
AU 34163/97 A
AU34163/97 A
AU 34163/97A
AU 3416397 A
AU3416397 A
AU 3416397A
AU 714694 B2
AU714694 B2
AU 714694B2
Authority
AU
Australia
Prior art keywords
composition
seed oil
acid
borage seed
emulsion
Prior art date
1996-08-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU34163/97A
Other versions

AU3416397A
(en

Inventor
John Brian Bartolone
Stephan Samuel Habif
Falguni Snehal Nanavaty
Dennis Brian Sinfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Unilever PLC

Original Assignee
Unilever PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1996-08-30
Filing date
1997-08-13
Publication date
2000-01-06

1997-08-13
Application filed by Unilever PLC
filed
Critical
Unilever PLC

1998-03-05
Publication of AU3416397A
publication
Critical
patent/AU3416397A/en

2000-01-06
Application granted
granted
Critical

2000-01-06
Publication of AU714694B2
publication
Critical
patent/AU714694B2/en

2017-08-13
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K8/00—Cosmetics or similar toiletry preparations

A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition

A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof

A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K8/00—Cosmetics or similar toiletry preparations

A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition

A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds

A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen

A61K8/36—Carboxylic acids; Salts or anhydrides thereof

A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K8/00—Cosmetics or similar toiletry preparations

A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition

A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds

A61K8/67—Vitamins

A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P17/00—Drugs for dermatological disorders

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

A61Q19/00—Preparations for care of the skin

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects

A61K2800/74—Biological properties of particular ingredients

A61K2800/75—Anti-irritant

Description

AUSTRALIA
PATENTS ACT 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT
C
**C
TITLE OF INVENTION BORAGE SEED OIL AS AN ANTI-IRRITANT IN COMPOSITIONS CONTAINING HYDROXY ACIDS OR RETINOIDS Name and Address of Applicant: UNILEVER AUSTRALIA LIMITED of 20-22 CAMBRIDGE STREET, EPPING NSW 2121 The following statement is a full description of this invention, including the best method of performing it known to me:-
C
C
J6362 BORAGE SEED OIL AS AN ANTI-IRRITANT IN COMPOSITIONS CONTAINING HYDROXY ACIDS OR RETINOIDS FIELD OF THE INVENTION The invention relates to compositions containing borage seed and hydroxy acids or retinoids and a method for reducing or eliminating skin irritation and/or sting.
BACKGROUND OF THE INVENTION Hydroxy acids (HAs) and retinoids have been proven to deliver cosmetic benefits, such as improvement in the appearance of photodamaged or naturally aged skin, skin lightening, treatment of age spots, etc. Unfortunately, their use at high concentrations may occasionally be associated with skin irritation, e.g. skin redness and stinging sensation o upon application. The irritation can be ameliorated by lowering the amount of an active ingredient in the composition or by reducing the active’s penetration through the skin. A serious drawback of both approaches is that the efficacy is impaired. The HA related irritation can be reduced by raising the composition’s pH but this method yields reduced efficacy due to a decreased HA penetration through the skin. It is desirable to reduce or *°eeo eliminate the irritation potential of HAs and/or retinoids while maintaining their efficacy.
.**European Patent Application 0631722 (Johnson Johnson) discloses the use of glycolic acid to reduce irritation of the skin by retinol. U.S. Patent 5,252,604 (Nagy et al.) teaches the use of tocopherols for retinoic acid induced irritation. U.S. Patent 5,516,793 (Duffy) discloses the use of ascorbic acid to ameliorate the irritation caused by various topical ingredients, including HAs and retinoids.
topical ingredients, including HAs and retinoids.
J6362 U.S. Patent 5,476,661 (Pillai et al.) discloses cosmetic compositions containing hydroxycalciferol and a lipid ingredient. Numerous optional ingredients are listed among which are mentioned HAs and/or retinoids and unsaturated fatty acids, such as gamma linolenic acid (GLA). Pillai et al. do not address the problem of skin irritation, do not teach the use of any agent for reducing skin irritation and do not teach the use of borage seed oil.
European Patent Application 0416855 (Efamol) discloses treatment of skin damage due to radiotherapy with gamma linolenic acid (GLA) and also teaches a variety of suitable plant sources of GLA, including Borage species. PCT application WO 90/07331 (Went) teaches treatment of inflammation arising from arthritis or headache by topical application of GLA; borage seed is taught as a suitable source. European Patent Application 0173478 (Efamol) discloses treatment of inflammatory skin disorders with compositions containing GLA and glucocorticoids; borage species such as Borago officinalis is mentioned as a rich *source of GLA. French patent 2,704,390 (Boiron) discloses an oral supplement containing borage seed oil to provide anti-aging benefits to skin. French patent 2,604,624 (Parfums SRochas) discloses skin care compositions containing polyunsaturated carboxylic acids, such as GLA; borage is said to be rich in GLA. U.S. Patent 5,445,822 (Bracco) discloses cosmetic compositions containing polyunsaturated acids such as GLA.
Great Britain Patent 2,271,928 (Laing) discloses the use of borage family plant extracts for alleviation of skin disorders and irritations.
Tollesson et al., «Transepidermal Water Loss and Water Content in the Stratum Corneum in Infantile Sebhorroeic Dermatitis», Acta Derm Venereol (Sweden), Feb. 1993, 73 p. 18-20, disclose the use of topically applied borage oil for treatment of sebhorroeic J6362 dermatitis. Bahmer et al., ‘Treatment of Atopic Dermatitis with Borage Seed Oil (Glandol) A Time Series Analytic Study», Kinderarztl Prax (Germany), Oct. 1992, 60 p. 199-202, disclose the use of borage oil for the treatment of atopic dermatitis.
The art discussed above does not teach any compositions containing borage seed oil in combination with HAs and/or retinoids. The art does not teach the use of GLA or borage seed oil to reduce irritation or sting associated with the use of HAs and/or retinoids.
Furthermore, it was found as part of the present invention that among GLA containing plant sources borage seed oil was particularly effective at ameliorating irritation induced by HAs or retinoids and that this effect could not be attributed merely to the presence of GLA in the borage seed oil.
SUMMARY OF THE INVENTION The present invention includes, in part, a compositions containing a cosmetic benefit ingredient selected from the group consisting of hydroxy acids and certain retinoids and further containing borage seed oil as an anti-irritant.
The invention also provides a method for reducing irritation or sting caused by the topical application of a composition containing HAs or retinoids, the method comprising topically applying borage seed oil. According to the inventive method, borage seed oil may be co-present with HAs and/or retinoids in the same composition, or borage seed oil may be applied from a separate composition.
According to the present invention, by virtue of topical application of borage seed oil, the irritation induced by the topical application of HAs and/or retinoids is reduced or J6362 eliminated. It has been found as part of the present invention that not all known antiirritants, even those that contain GLA, ameliorate HAs/retinoid induced irritation.
DETAILED DESCRIPTION OF THE INVENTION All amounts are by weight of the oil-in-water emulsion, unless otherwise specified.
Borage seed oil is an essential ingredient of the inventive compositions and methods.
Borage seed oil is obtained from the seeds of borage plant, also known as Borago officinalis L. (Boraginaceae), which is an herbaceous annual plant, native to Europe, Asia Minor and North Africa, naturalized in the United States. The seed oil contains: gammalinoleic acid (GLA), sterols campestrol and sitosterol), tocopherols, linoleic acid oleic acid (-14.5 palmitic amabiline, etc. See Whipkey et al., «In Vivo and In Vitro Lipid Accumulation in Borago officinalis JAOCS, 65 979-984 (1988); and Leung et al., «Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics», 2nd ed., John Wiley Sons, Inc., New York (1996).
Borage seed oil is employed according to the present invention to reduce or eliminate the skin irritation and/or sting caused by hydroxy acids and/or retinoids.
The amount of borage seed oil in the inventive compositions ranges generally from 0.05% to 10 preferably from 0.1% to most preferably from 0.5% to 2%.
J6362 Hydroxyacids enhance proliferation and increase ceramide biosynthesis in keratinocytes, increase epidermal thickness, and increase desquamation of normal skin resulting in smoother, younger looking skin.
The hydroxy acid can be chosen from a-hydroxy acids, p-hydroxyacids (e.g.
salicylic acid), other hydroxycarboxylic acids dihydroxycarboxylic acid, hydroxydicarboxylic, hydroxytricarboxylic) and mixtures thereof or combination of their stereoisomers (DL, D or L).
Preferably the hydroxy acid (ii) is chosen from a-hydroxy acids having the general structure (1)
OH
MCHCOOH (1) where M is H or a saturated or an unsaturated, straight or branched hydrocarbon chain containing from 1 to 27 carbon atoms.
Even more preferably the hydroxy acid is chosen from lactic acid, 2-hydroxyoctanoic acid, hydroxylauric, glycolic acid, and mixtures thereof. When stereo isomers exist, Lisomer is most preferred.
The keto acids can be chosen from a-keto acids, p-keto acids and mixtures thereof.
J6362 A particularly preferred a-keto acid is 2-keto octanoic acid.
It is to be understood that depending on the pH of the composition, the hydroxy acid may be present as a salt, e.g. ammonium or potassium or sodium salt.
Although the inventive compositions may have any pH in the general range of 2.5 to the inventive compositions are particularly useful when they are at an acidic pH (especially if they contain a hydroxy acid), preferably 3-5 and most preferably at a pH of 3- 4, because such compositions are particularly irritating.
Retinoids enhance keratinocyte proliferation in vitro, increase epidermal thickness and increase collagen synthesis by dermal fibroblasts. This results in protection from sun damage and smoothing of wrinkled skin. The term «retinoids» as used herein includes retinoic acid, retinol, retinal and C2-Cs retinyl esters. Included in the term «retinoic acid» are 13-cis retinoic acid and all-trans retinoic acid.
The term «retinol» includes the following isomers of retinol: all-trans-retinol, 13-cisretinol, 11-cis-retinol, 9-cis-retinol, 3,4-didehydro-retinol. Preferred isomers are all-transretinol, 13-cis-retinol, 3,4-didehydro-retinol, 9-cis-retinol. Most preferred is all-trans-retinol, due to its wide commercial availability.
a.
Retinyl ester is an ester of retinol. The term «retinol» has been defined above.
Retinyl esters suitable for use in the present invention are C2-C5 esters of retinol, a preferably C2 and C3 esters, and most preferably C2 ester because it is more commonly available. Retinyl esters included in the invention are also known as: retinyl acetate, retinyl i propionate, retinyl butyrate, and retinyl pentanolate.
J6362 A particular advantage of the inventive compositions is that higher amounts of hydroxy acids or retinoids may be employed without causing skin irritation. Preferably the amount of the hydroxy acid component present in the composition according to the invention is from 0.01 to 20%, more preferably from 2 to 12% and most preferably from 4 to 12% by weight.
A retinoid may be present in the inventive compositions in an amount 33 to 330,000 IU per gram of the composition, preferably 330 to 16,500 IU, most preferably 1,650 to 6,600 IU. Again, a higher amount of a retinoid may be employed in the inventive compositions without causing skin irritation, due to the co-presence of borage seed oil.
Most preferred inventive compositions containing borage seed oil anti-irritant include retinol and/or glycolic acid and/or lactic acid because these ingredients have been found to cause irritation yet they were found to be particularly efficacious at delivering cosmetic benefits.
The skin treatment composition of the invention also includes a cosmetically acceptable vehicle or a carrier which is inert, usually an ingredient present in the highest amounts, and functioning to deliver active ingredients.
Vehicles other than or in addition to water can include liquid or solid emollients, solvents, humectants, thickeners and powders. An especially preferred nonaqueous carrier is a polydimethyl siloxane and/or a polydimethyl phenyl siloxane. Silicones of this invention may be those with viscosities ranging anywhere from about 10 to 10,000,000mm 2 s(centistokes) at 250C. Especially desirable are mixtures of low and 9 J6362 high viscosity silicones. These silicones are available from the General Electric Company under trademarks Vicasil, SE and SF and from the Dow Coming Company under the 200 and 550 Series.
The cosmetically acceptable vehicle will usually form from 5% to 99.9%, preferably from 25% to 80% by weight of the composition, and can, in the absence of other cosmetic adjuncts, form the balance of the composition.
According to the present invention, the vehicle is at least 80 wt.% water, by weight of the vehicle. The inventive compositions are oil-water emulsions, in order to improve dermal delivery of hydroxy acids (See Sah «An in-vitro study of the effect of formulation variables and product structure on the delivery of alpha-hydroxy acid (Lactic acid) to skin», MS Thesis, Department of Pharmaceutical Sciences of the College of Pharmacy, University of Cincinnati, OH, July 1996). Such improved delivery is frequently accompanied by increased irritation/sting, making the use of borage seed oil in such emulsions particularly critical. In the oil-in-water emulsions according to the present invention, water comprises at least 50 wt.% of the inventive emulsion, most preferably from 60 to 80 by weight of the composition.
Optional Skin Benefit Materials and Cosmetic Adjuncts An oil or oily material may be present, together with an emulsifier to provide either an oil-in-water emulsion.
Emollients are often incorporated into cosmetic compositions of the present invention. Levels of such emollients may range from 0.5% to 50%, preferably between J6362 and 30% by weight of the total composition. Emollients may be classified under such general chemical categories as esters, fatty acids and alcohols, polyols and hydrocarbons.
Esters may be mono- or di-esters. Acceptable examples of fatty di-esters include dibutyl adipate, diethyl sebacate, diisopropyl dimerate, and dioctyl succinate. Acceptable branched chain fatty esters include 2-ethyl-hexyl myristate, isopropyl stearate and isostearyl palmitate. Acceptable tribasic acid esters include triisopropyl trilinoleate and trilauryl citrate. Acceptable straight chain fatty esters include lauryl palmitate, myristyl lactate, oleyl eurcate and stearyl oleate. Preferred esters include coco-caprylate/caprate (a blend of coco-caprylate and coco-caprate), propylene glycol myristyl ether acetate, diisopropyl adipate and cetyl octanoate.
Suitable fatty alcohols and acids include those compounds having from 10 to carbon atoms. Especially preferred are such compounds such as cetyl, myristyl, palmitic and stearyl alcohols and acids.
Among the polyols which may serve as emollients are linear and branched chain alkyl polyhydroxyl compounds. For example, propylene glycol, sorbitol and glycerin are Spreferred. Also useful may be polymeric polyols such as poly-propylene glycol and polyethylene glycol. Butylene and propylene glycol are also especially preferred as penetration enhancers.
Exemplary hydrocarbons which may serve as emollients are those having hydrocarbon chains anywhere from 12 to 30 carbon atoms. Specific examples include mineral oil, petroleum jelly, squalene and isoparaffins.
a J6362 The inventive compositions preferably include sunscreens. Sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are the derivatives of PABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively. The exact amount of sunscreen employed in the emulsions can vary depending upon the degree of protection desired from the sun’s UV radiation.
Another category of functional ingredients within the cosmetic compositions of the present invention are thickeners. A thickener will usually be present in amounts anywhere from 0.1 to 20% by weight, preferably from about 0.5% to 10% by weight of the composition. Exemplary thickeners are cross-linked polyacrylate materials available under the trademark Carbopol from the B.F. Goodrich Company. Gums may be employed such as xanthan, carrageenan, gelatin, karaya, pectin and locust beans gum. Under certain circumstances the thickening function may be accomplished by a material also serving as a silicone or emollient. For instance, silicone gums in excess of 10 centistokes and esters such as glycerol stearate have dual functionality.
Powders may be incorporated into the cosmetic composition of the invention. These powders include chalk, talc, kaolin, starch, smectite clays, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, aluminum starch octenyl succinate and mixtures thereof.
Other adjunct minor components may also be incorporated into the cosmetic compositions. These ingredients may include coloring agents, opacifiers and perfumes.
J6362 Amounts of these other adjunct minor components may range anywhere from 0.001% up to 20% by weight of the composition.
Use of the Emulsion The composition according to the invention is intended primarily as a product for topical application to human skin, especially for conditioning and smoothening the skin, and preventing or reducing the appearance of lined, wrinkled or aged skin.
In use, a small quantity of the composition, for example from 1 to 100 ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.
According to the present inventive method, the skin irritation/sting caused by the active ingredient is reduced or eliminated by topical application of borage seed oil. The borage seed oil may be co-present with the active, or it may be applied to the skin separately from the active.
a J6362 Product Form and Packaging The emulsion of the invention can be formulated as a lotion, a fluid cream, a cream or a gel. The composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator, or a capsule, or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar.
The invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.
The borage seed oil may be packaged separately from the composition containing HAs and/or retinoids.
The following specific examples further illustrate the invention. Borage seed oil employed in the examples was obtained from Canamono Inc. (Northport, NY).
EXAMPLE 1 a* a Seventeen subjects were tested according to Irritation Test Method described below.
6 ft e 4pql J6362 Irritation Test Method Four Exposure Patch Test: The objective was to compare the level of irritation produced by various test materials after repeated patch applications. The test materials were held in contact with the skin under occlusive conditions. The outer upper arm of the panelist was designated as the area of application. Bandage type dressing (Scanpor7 tape) was used to hold the patches (25 mm Hill Top7 Chamber fitted with 18 mm diameter disc of Webril7 padding) into place. Both upper arms of the panelist were used. Patches were applied in a balanced random order.
Patches were applied at 9:00 o’clock Monday morning and removed at 9:00 o’clock Tuesday morning (24 hour exposure). A new set of patches was applied at 3:00 o’clock Tuesday afternoon and removed Wednesday morning at 9:00 o’clock (18 hour exposure).
A third set of patches was applied at 3:00 o’clock Wednesday afternoon and removed Thursday morning at 9:00 o’clock (18 hour exposure). A final set of patches was applied at 3:00 o’clock Thursday afternoon and removed Friday morning at 9:00 o’clock (18 hour exposure).
Each time the patches were removed, the sites were rinsed with warm water and patted dry. The test sites were then marked with a surgical skin marking pen to ensure location for grading and subsequent patch applications. Test sites were evaluated at 3:00 p.m. on Tuesday, Wednesday, Thursday and Friday of the study, prior to re-patching.
Skin irritation such as moderate redness, dryness, and/or itching of the test site is expected. Swelling of the test sites is possible. If any test has moderate redness or any swelling at evaluation, that particular test site should not be repatched.
J6362 The test sites on each arm were visually ranked by two trained examiners under consistent lighting. The test sites were ranked in order of severity. The examiner ranking responses at the first evaluation period continued ranking the sites each day throughout the study.
In ranking the reactions, the site with the most severe response was given the lowest score. The site with the second most severe response was given the second lowest score, etc. There was no forced ranking. If two or more sites had no response or the same response (no difference between sites), an average of the ranks was assigned.
If a site has been discontinued, due to degree of irritation the site retained the rank it received at the time dosing was discontinued.
9 Statistical Analysis The ranking results from the patch treatments were statistically compared by nonparametric statistical methods. The test materials containing the anti-irritants were compared to the corresponding control containing only hydroxy acid and/or retinoid, using Friedman’s Rank Sum. Treatments were compared to the Formula 2 (control) at each evaluation point using Friedman’s analysis with the panelist acting as a block each panelist was tested with each test treatment), p-value of #0.1 was considered statistically significant.
An oil-in-water emulsion base was prepared having the following formula.
J6362 BASE FORMULA FULL CHEMICAL NAME TRADE NAME AND ACTIVE AS WT. OR RECEIVED CFTANAME water, Dl 46.54 disodium EDTA Seguesterene Na2 0.05 magnesium aluminum silicate Veegumn Ultra 0.6 methyl paraben Methyl Paraben 0.15 simethicone DC Antifoamn Emulsion 0.01 butylene glycol 1,3 Butylene Glycol 1,3 hydroxyethylcel Iu lose Natrosol 250HHR glycerine, USP Glycerine USP xanthan gum Keltrol 1000 0.2 triethanolamnine Triethanolamnine 99 ()1.2 stearic acid Pristerene 4911 propyl paraben NF Propylparaben NF 0.1 _glyceryl hydrostearate Naturechemn GMHS stearyl alcohol Lanette 18DEO isostearyl palmitate Protachemn ISP C 12-15 alcohols octanoate Hetester FAO dimethicone Silicone Fluid 200 (50cts) cholesterol NF Cholesterol NF sorbitan stearate Sorbitan Stearate butylated hydroxytoluene Emnbanox BHT 0.05 tocopheryl acetate -Vitamnin E Acetate 0.1 PEG-i100 stearate MYRJ 592.
water, Dl g.s. to 99.80 aipha-bisabolol Alpha-bisabolol 0.2 pH Compositions 1-5 containing ingredients as indicated in Table 1 were tested using the Irritation Test Method. Ingredients added to Compositions 2-5 were added in place of water in the Base Formula. Compositions 2-5 had a pH=3.8 0.2. The results that were obtained are summarized in Table 1. The higher the Sum of Ranks, the less severe the irritation.
0* So S 0
S
SS
S 0 05,0 S. SO 9 S sees 0 *so* Vedee 6 TABLE 1 *Irritation Test Results J6362 COMPOSITION INGREDIENTS SUM OF GLA
RANKS
(DAY 4) 1 Base Formula 6 8 2 Control: Base Formula 8% Glycolic 46.5 Acid and 0.075% Retinol ammonium hydroxide to pH 3.8 3 Composition #2 0.5% Borage Seed 6 9 .5a 0.115 Oil 4 Composition #2 3% Black Currant 58.0 0.51 SSeed Oil Composition #2 1% Sambucus 44.5 r a.
a u a a Significantly less irritating than composition #2.
It can be seen from the results in Table 1 that after four exposures, 8% glycolic acid with 0.075% retinol was significantly more irritating than Base formula 8% glycolic acid and 0.075% retinol was also significantly more irritating than the same composition containing Borage seed oil By contrast, 1% Sambucus or 3% Black Currant Seed Oil did not significantly reduce the irritation.
Sambucus and Black currant seed oil are known anti-irritants. Black currant seed oil also contains 17% GLA. However, neither agent was effective in reducing alpha hydroxy acid/retinol induced irritation.
The art teaches that the formulation with higher total GLA would be expected to be less irritating. In this case, the black currant seed oil formulation would have been expected to be less irritating than the borage seed oil formulation. Surprisingly, we found that the borage seed oil formulation which contained a significantly lower concentration of J6362 GLA was less irritating than the black currant seed oil formulation, although the black currant seed oil formulation contained five times more GLA than borage seed oil.
COMPARATIVE EXAMPLE 2 Compositions 1, 2 and 6-9 containing ingredients as indicated in Table 2 were tested using the Irritation Test Method described in Example 1. Seventeen subjects were tested. Ingredients added to Compositions 2-9 were added in place of water in the Base Formula. Compositions 2-9 had a pH=3.8 0.2. The results that were obtained are summarized in Table 2. The higher the sum of ranks, the less is the irritation.
9 J6362 TABLE 2 Irritation Test Results INGREDIENTS SUM OF
RANKS
(DAY 4) Base Formula 74.5a Base Formula 8% Glycolic 61.5 0.075% Retinol ammonium hydroxide to pH 3.8 Composition #2 1% Green Tea 51.0 Composition #2 0.1% K2 54.5 Glycyrrohetinic Acid Composition #2 3% Quench T* 58.5 Composition #2 3% Polyol 57.0 Prepolymer 9.
9 9 e 9 9 9* 9 9 9 Statistically less irritating than composition #2.
An anti-irritant from Centerchem (containing water, butylene glycol, kola bean extract, guarana extract, and mate extract).
An anti-irritant from Penederm, Inc. (CFTA name PPG-12/SMDI).
It can be seen from the results in Table 2 that none of the anti-irritants tested (none contained GLA) were able to significantly reduce the irritation induced by composition #2 (containing 8% Glycolic Acid and 0.075% Retinol).
J6362 EXAMPLE 3 Compositions 10-13 containing ingredients as indicated in Table 3 were tested using the Irritation Test Method described in Example 1. Composition 10 was similar to composition 1 in Example 1, except that composition 10 additionally contained sodium stearyl lactylate, 0.1% retinyl palmitate and 0.1% hydroxy caprylic acid («Base Formula Ingredients added to Compositions 10-13 were added in place of water in the Base Formula. Composition 10 had a pH=7.8 0.5. Compositions 11-13 had a pH=3.8 0.2. The results that were obtained are summarized in Table 3. The higher the Sum of Ranks, the less severe the irritation.
TABLE 3 Irritation Test Results COMPOSITION INGREDIENT SUM OF GLA IN RANKS COMPOSITION (DAY 4) 10 Base Formula A 75.5 a 0 11 Base Formula A 8% 48.5 0 Glycolic Acid ammonium hydroxide to pH 3.8 12 Base Formula A 8% 44.5 0.125 Glycolic Acid 0.125% GLA ammonium hydroxide to pH 3.8 13 Base Formula A 8% 61.0 0.115 Glycolic Acid 0.5% Borage Seed oil ammonium hydroxide to pH 3.8 *0 a Statistically significant compared to composition #11.
J6362 It can be seen from the results in Table 3, that the addition of 8% glycolic acid (composition #11) significantly increased the irritation. Upon further addition of borage seed oil (composition the irritation was directionally reduced. By contrast, a composition which contained a similar amount of GLA as composition #13, but not from borage seed oil, did not at all reduce the irritation induced by glycolic acid. This again demonstrates that borage seed oil efficacy at reducing HA irritation is unique and cannot be attributed solely to the presence of GLA.
EXAMPLE 4 Twenty-one (21) subjects were tested according to the Irritation Test Method described in example 1.
Compositions 11, 13 and 14 containing ingredients as indicated in Table 4 were o tested using the Irritation Test Method. Ingredients added to Compositions 11, 13 and 14 were added in place of water in the Base Formula. The results that were obtained are summarized in Table 4. The higher the Sum of Ranks, the less severe the irritation.
e« J6362 TABLE 4 Irritation Test Results a..
a. *4 COMPOSITION INGREDIENTS SUM OF RANKS (DAY 4) GLA 11 Base Formula A 8% 52.0 Glycolic Acid ammonium hydroxide to pH 3.8 13 Composition #11 0.5% 65.5 0.115 Borage Seed Oil ammonium hydroxide to pH 3.8 14 Composition #11 1.0% 78.0 a 0.23 Borage Seed Oil ammonium hydroxide to pH 3.8 a Significantly less irritating than Composition #11.
It can be seen from the results in Table 4 that after four exposures, 8% glycolic acid was significantly more irritating than the same composition containing 1% Borage seed oil Upon addition of 0.5% Borage seed oil irritation was directionally less as was previously shown in Example 3.
Examples 5-9 illustrate skin care compositions according to the present invention.
The compositions can be processed in conventional manner. They are suitable for cosmetic use. In particular, the compositions are suitable for application to wrinkled, lined, rough, dry, flaky, aged and/or UV-damaged skin to improve the appearance and the feel thereof as well as for application to healthy skin to prevent or retard deterioration thereof.
EXAMPLE J6362 A typical oil-in-water emulsion within the scope of the invention is as follows: chemical name wt.% propylene glycol glycerin hydroxyethylcellulose magnesium aluminum silicate imidazolidinyl urea tetrasodium EDTA petrolatum isopropyl palmitate dimethicone cholesterol cetyl alcohol isostearic acid retinyl palmitate stearate peg-100 stearate sorbitan stearate borage seed oil glycolic acid ammonium hydroxide water DI 1 1 0.05 2 3 0.1 1 1 1 7 to pH qs to 100% a a.
a
S
a a J6362 EXAMPLE 6 Another typical oil-in-water emulsion within the scope of the invention is as follows: chemical name wt.% propylene glycol hydroxyethylcellulose magnesium aluminum silicate imidazolidinyl urea petrolatum isopropyl palmitate dimethicone cholesterol stearic acid isostearic acid glycerol stearate stearate peg-100 stearate sorbitan stearate cetyl alcohol borage seed oil glycolic acid ammonium hydroxide water DI 1 0.2 2 3 1 1 1 1 to pH 3.8 qs to 100% a a J6362 EXAMPLE 7 The following oil-in-water emulsion within the scope of the invention is prepared: chemical name glycerin tetrasodium EDTA cetyl alcohol stearyl alcohol mineral oil dimethicone cyclomethicone dimethiconol polyquaternium 37 steareth-21 steareth-2 salicylic acid borage seed oil triethanolamine water Dl wt.% 1 0.1 1 1 1 0.2 2 1 2 to pH qs to 100% a a a a a
S*
a a a. a.
a a a J6362 EXAMPLE 8 The following oil-in-water emulsion within the scope of the invention is prepared: chemical name wt.% xanthan gum disodium EDTA sodium PCA diazodinyl urea titanium dioxide stearic acid cyclomethicone cetyl alcohol glyceryl stearate peg-100 stearate steareth-2 lecithin tocopherol octyl methoxycinnamate borage seed oil glycolic acid malic acid lactic acid green tea extract triethanolamine water DI 0.2 0.1 0.3 1 3 0.3 0.2 0.2 6 3 2 2 1 to pH 3.8 qs to 100% a a J6362 EXAMPLE 9 The following oil-in-water emulsion within the scope of the invention is prepared: chemical name all-trans retinoic acid light mineral oil stearoxytri methyls ilane and stearyl alcohol dimethicone stearyl stearate quaternium-1 5 peg-22 dodecyl glycol copolymer borage seed oil sorbitol methyl paraben disodium EDTA butylated hydroxytoluene water Dl 0.05 2 3 1 1 0.2 0.1 0. 1 qs to 100% a. a a a.
a a.
a a a a a a.
a a. a.
a a a.aa..
a

Claims (9)

1. A cosmetic oil-in-water emulsion comprising: a cosmetic benefit ingredient selected from the group consisting of a hydroxy acid, retinol, retinoic acid, retinal, C 2 -Cs retinyl ester and mixtures thereof; (ii) borage seed oil in an amount in an amount of from 0.05 to 10 and (iii) at least 50% water.

2. The emulsion of claim 1 wherein the cosmetic benefit ingredient is a hydroxy acid, which is present in an amount of from 0.01 to 20 wt%.

3. The emulsion of claim 2 wherein the amount of the hydroxy acid is from 2 to 12% by weight of the composition.

4. The emulsion of claim 1 wherein the cosmetic benefit ingredient is a retinol or a retinyl ester, which is present in an amount of from 33 to 330,000 IU per gram of the composition.

The emulsion of claim 1 wherein the cosmetic benefit ingredient is selected from the group consisting of retinol, glycolic acid, lactic acid, and mixtures thereof.

6. The emulsion of any one of the claims 1 5, wherein the composition is an oil-in- water emulsion.

7. The emulsion of any one pf claims 1 6, wherein the pH of the composition is in the range of from 3 to J6362

8. A method for reducing irritation or sting caused by the topical application of a composition containing a hydroxyacid or a retinoid, the method comprising topically applying borage seed oil. D AT ED -A\J Signed for and on behalf of UNILEVER PLC by Unilever Australia Limited B. F. JONES,- C tary.

AU34163/97A
1996-08-30
1997-08-13
Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids

Ceased

AU714694B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US08/706009

1996-08-30

US08/706,009

US5690947A
(en)

1996-08-30
1996-08-30
Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids

Publications (2)

Publication Number
Publication Date

AU3416397A

AU3416397A
(en)

1998-03-05

AU714694B2
true

AU714694B2
(en)

2000-01-06

Family
ID=24835840
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU34163/97A
Ceased

AU714694B2
(en)

1996-08-30
1997-08-13
Borage seed oil as an anti-irritant in compositions containing hydroxy acids or retinoids

Country Status (16)

Country
Link

US
(2)

US5690947A
(en)

EP
(1)

EP0826366B1
(en)

JP
(1)

JP3832939B2
(en)

KR
(1)

KR100349424B1
(en)

CN
(1)

CN1100528C
(en)

AR
(1)

AR008833A1
(en)

AU
(1)

AU714694B2
(en)

BR
(1)

BR9704529B1
(en)

CA
(1)

CA2212850C
(en)

DE
(1)

DE69725804T2
(en)

ES
(1)

ES2210460T3
(en)

ID
(1)

ID18151A
(en)

IN
(1)

IN189566B
(en)

NZ
(1)

NZ328512A
(en)

TW
(1)

TW431890B
(en)

ZA
(1)

ZA977666B
(en)

Families Citing this family (51)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US6340485B1
(en)

1996-06-03
2002-01-22
Croda International Plc
Compositions and uses thereof

US5855893A
(en)

1997-02-14
1999-01-05
Elizabeth Arden Co., Division Of Conopco, Inc.
Trichodesma lanicum seed extract as an anti-irritant in compositions containing hydroxy acids or retinoids

JPH10265362A
(en)

1997-03-19
1998-10-06
Yakult Honsha Co Ltd
Cosmetic

US6270780B1
(en)

1997-07-25
2001-08-07
Chesebrough-Pond’s Usa Co., Division Of Conopco
Cosmetic compositions containing resveratrol

FR2773074B1
(en)

1997-12-30
2001-02-16
Led Evolution Dermatolog

COMPOSITION BASED ON ALPHA-HYDROXY-ACIDS AND CERAMIDES FOR TOPICAL USE IN THE TREATMENT OF DERMATOLOGICAL CONDITIONS

JP3634139B2
(en)

1998-02-10
2005-03-30
株式会社資生堂

Oil-in-water emulsion composition

KR100760167B1
(en)

1998-02-10
2007-09-20
가부시키가이샤 시세이도
Oil-in-water type emulsified compositions

US6143309A
(en)

1998-03-12
2000-11-07
Archimica (Florida), Inc.
Delivery of hydroxy carboxylic acids

US6683069B1
(en)

1998-04-02
2004-01-27
Regents Of The University Of Michigan
Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin

TWI234455B
(en)

1998-04-02
2005-06-21
Univ Michigan
Methods and compositions for reducing UV-induced inhibition of collagen synthesis in human skin

US6203805B1
(en)

1998-11-10
2001-03-20
Color Access, Inc.
Topical compositions containing whey proteins

JP4035258B2
(en)

1999-05-10
2008-01-16
花王株式会社

Skin preparation

US20050009717A1
(en)

1999-07-01
2005-01-13
Lukenbach Elvin R.
Foaming make-up removing cleansing compositions

US7074747B1
(en)

1999-07-01
2006-07-11
Johnson & Johnson Consumer Companies, Inc.
Cleansing compositions

AU5764800A
(en)

1999-07-01
2001-01-22
Johnson & Johnson Consumer Companies, Inc.
Cleansing compositions

US6762158B2
(en)

1999-07-01
2004-07-13
Johnson & Johnson Consumer Companies, Inc.
Personal care compositions comprising liquid ester mixtures

GB9918028D0
(en)

1999-07-30
1999-09-29
Unilever Plc
Skin care composition

WO2002000240A2
(en)

2000-06-27
2002-01-03
Qualilife Pharmaceuticals Inc.
Compositions and methods for treating females sexual response

US6583184B1
(en)

2000-11-27
2003-06-24
Avon Products, Inc.
Compositions having comfrey and methods for reducing retinoid-induced skin irritation

DE10063658A1
(en)

2000-12-20
2002-07-04
Beiersdorf Ag
Cosmetic or dermatological emulsion, useful for skin care, e.g. for treating rough skin, comprises sterols and/or fatty acids, polyol mono- and/or diesters, sorbitol monoester, ethoxylated fatty acids and fatty alcohols

DE10063660A1
(en)

2000-12-20
2002-07-04
Beiersdorf Ag
Cosmetic or dermatological emulsion, useful for e.g. treating rough skin, comprises sterols and/or fatty acids, polyol mono- and/or diesters, sorbitol monoester, ethoxylated fatty acids and fatty alcohols

GB0110408D0
(en)

2001-04-27
2001-06-20
Smithkline Beecham Plc
Composition

DE10139582A1
(en)

2001-08-10
2003-02-20
Beiersdorf Ag
W/O/W emulsions useful e.g. cleansing, skin-care or anti-acne agents comprises a combination of steroids, fatty acids and optionally ethoxylated esters

DE10139580A1
(en)

2001-08-10
2003-02-20
Beiersdorf Ag
O/W emulsions useful e.g. cleansing, skin-care or anti-acne agents comprise a combination of steroids or fatty acids with optionally ethoxylated esters

US20030165546A1
(en)

2002-03-04
2003-09-04
The Procter & Gamble Company
Stable personal care compositions containing a retinoid

DE10239648A1
(en)

2002-08-29
2004-03-11
Beiersdorf Ag

Cleanser

US20040126351A1
(en)

2002-12-26
2004-07-01
Avon Products, Inc.
Topical composition having natural skin anti-irritant ingredient and method of use

EP1720605A4
(en)

2003-06-23
2007-10-24
Transpharma Medical Ltd
Transdermal delivery system for cosmetic agents

KR101365282B1
(en)

2005-09-23
2014-02-19
디에스엠 아이피 어셋츠 비.브이.
Cosmetic compositions comprising hydroxyfatty acids

CN100366235C
(en)

2006-01-25
2008-02-06
刘晓芸
Skin physiological maintenance oil for male

FR2898046A1
(en)

2006-03-03
2007-09-07
Oreal
Topical composition useful for cleaning, as make up remover, care and/or make up of skin and to treat acne, comprises alpha hydroxy acids and beta hydroxy acids, and fatty alcohol, in the form of oil-in-water emulsion

DE102006031762A1
(en)

2006-07-05
2008-01-10
Lancaster Group Gmbh

Cosmetic preparation with a skin care complex with anti-aging effect

US20080095720A1
(en)

2006-10-18
2008-04-24
Conopco, Inc., D/B/A Unilever
Skin Benefit Compositions with a Vanilloid Receptor Antagonist

US20090137534A1
(en)

2007-11-26
2009-05-28
Chaudhuri Ratan K
Skin treatment compositions and methods

CA2747939C
(en)

2008-12-22
2016-11-08
Thierry Oddos
A composition comprising a retinoid and method of treating skin conditions

FR2991176B1
(en)

2012-06-01
2014-12-19
Galderma Res & Dev

TOPICAL COMPOSITIONS CONTAINING SOLUBILIZED RETINOID OF HYDROGLYCOLIC GEL TYPE

FR2991177B1
(en)

2012-06-01
2014-12-19
Galderma Res & Dev

TOPICAL COMPOSITIONS, CONTAINING RETINOID, EMULSION TYPE EMULSION IN WATER WITHOUT EMULSIFIER

US9084778B2
(en)

2012-06-01
2015-07-21
Galderma Research & Development
Topical compositions containing a retinoid of the oil-in-water emulsion type

US9023399B2
(en)

2012-11-16
2015-05-05
NU Technology, LLC
Water-soluble anti-inflammatory cream with natural ingredients base

JP6291031B2
(en)

2013-04-05
2018-03-14
ザプロクターアンドギャンブルカンパニー

Personal care composition containing pre-emulsified formulation

US20150051296A1
(en)

2013-08-13
2015-02-19
Access Business Group Internaional LLC
Use of fatty acid to reduce skin irritation associated with retinoid therapy

US10806688B2
(en)

2014-10-03
2020-10-20
The Procter And Gamble Company
Method of achieving improved volume and combability using an anti-dandruff personal care composition comprising a pre-emulsified formulation

US9993404B2
(en)

2015-01-15
2018-06-12
The Procter & Gamble Company
Translucent hair conditioning composition

EA034808B1
(en)

2015-07-13
2020-03-24
Др. Редди’С Лабораториз Лтд.
Topical retinoid compositions

MX2018008913A
(en)

2016-01-20
2019-05-06
Procter & Gamble
Hair conditioning composition comprising monoalkyl glyceryl ether.

EP3641725A1
(en)

2017-06-23
2020-04-29
The Procter and Gamble Company
Composition and method for improving the appearance of skin

EP3817717A1
(en)

2018-07-03
2021-05-12
The Procter & Gamble Company
Method of treating a skin condition

US11389382B2
(en)

2019-09-26
2022-07-19
L’oreal
Biphase chemical peel

US10959933B1
(en)

2020-06-01
2021-03-30
The Procter & Gamble Company
Low pH skin care composition and methods of using the same

US11583488B2
(en)

2020-06-01
2023-02-21
The Procter & Gamble Company
Method of improving penetration of a vitamin B3 compound into skin

KR102420820B1
(en)

2022-03-23
2022-07-18
(주)아크에이르
Composition for inhibiting skin inflammation comprising Tretinoin Potassium Salt as an active ingredient.

Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5587149A
(en)

1995-02-06
1996-12-24

R.P. Scherer Corporation

Topical application emulsions

Family Cites Families (20)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

GB8420771D0
(en)

1984-08-15
1984-09-19
Efamol Ltd
Treatment of skin disorders

FR2588187B1
(en)

1985-10-07
1989-04-14
Rochas Parfums

NEW COSMETIC OR DERMATOLOGICAL COMPOSITIONS RICH IN ESSENTIAL FATTY ACIDS PRESENT BOTH IN THE FORM OF TRIGLYCERIDES AND IN THE FREE OR SALIFIED FORM

IE60704B1
(en)

1987-01-19
1994-08-10
Rochas Parfums
Cosmetic and dermatological compositions including an extract of marianum sillybum rich in sillymarine associated with essential fatty acids

US5039513A
(en)

1987-10-22
1991-08-13
The Procter & Gamble Company
Photoprotection compositions and methods comprising sorbohydroxamic acid

AU629286B2
(en)

1988-12-23
1992-10-01
Arthur George Bolt
Anti-inflammatory liniment

GB8920228D0
(en)

1989-09-07
1989-10-18
Efamol Holdings
Fatty acid therapy

US5082661A
(en)

1990-09-26
1992-01-21
Elizabeth Arden Co., Division Of Conopco, Inc.
Odorless cosmetic compositions in gelatin capsules

FR2674127B1
(en)

1991-03-20
1993-06-11
Oreal

COSMETIC COMPOSITION FOR FIGHTING AGING OF THE SKIN CONTAINING AT LEAST ONE RETINOUIDE AND AT LEAST ONE DIALKYL- OR TRIALKYLXANTHINE.

FR2681783B1
(en)

1991-09-27
1996-07-26
Bourjois Sa

MIXTURE OF VEGETABLE OILS RICH IN ESSENTIAL FATTY ACIDS AND ITS USE IN COSMETIC COMPOSITIONS.

AU3931193A
(en)

1992-03-20
1993-10-21
Micro Motion, Inc.
Improved viscometer for sanitary applications

US5252604A
(en)

1992-07-10
1993-10-12
Hoffmann-La Roche Inc.
Compositions of retinoic acids and tocopherol for prevention of dermatitis

GB2271928A
(en)

1992-10-27
1994-05-04
Rose Mary Elizabeth Laing
Borage plant extracts

US5516793A
(en)

1993-04-26
1996-05-14
Avon Products, Inc.
Use of ascorbic acid to reduce irritation of topically applied active ingredients

DK0624363T3
(en)

1993-05-10
2000-02-28
Nestle Sa

Lipid composition for cosmetic products containing triglycerides of unsaturated fatty acids

US5310556A
(en)

1993-06-09
1994-05-10
Chesebrough-Pond’s Usa Co., Division Of Conopco, Inc.
Cosmetic composition

US5441740A
(en)

1994-05-06
1995-08-15
Longevity Network. Ltd.
Cosmetic composition containing alpha hydroxyacids, salicyclic acid, and enzyme mixture of bromelain and papain

JP3655633B2
(en)

1994-07-22
2005-06-02
コレティカ

Lipophilic hydroxy acids, their cosmetic and medicinal uses and methods for their production

US5476661A
(en)

1994-10-21
1995-12-19
Elizabeth Arden Co., Division Of Conopco, Inc.
Compositions for topical application to skin, hair and nails

EP0796077B1
(en)

1994-12-20
2002-06-05
L’oreal
Skin revitalizing makeup composition

US5560917A
(en)

1995-02-01
1996-10-01
Maybelline Intermediate Company
Cosmetic makeup composition

1996

1996-08-30
US
US08/706,009
patent/US5690947A/en
not_active
Expired – Lifetime

1997

1997-08-01
ES
ES97305810T
patent/ES2210460T3/en
not_active
Expired – Lifetime

1997-08-01
DE
DE69725804T
patent/DE69725804T2/en
not_active
Expired – Lifetime

1997-08-01
EP
EP97305810A
patent/EP0826366B1/en
not_active
Expired – Lifetime

1997-08-06
NZ
NZ328512A
patent/NZ328512A/en
not_active
IP Right Cessation

1997-08-12
IN
IN479BO1997
patent/IN189566B/en
unknown

1997-08-13
CA
CA002212850A
patent/CA2212850C/en
not_active
Expired – Lifetime

1997-08-13
AU
AU34163/97A
patent/AU714694B2/en
not_active
Ceased

1997-08-26
ZA
ZA977666A
patent/ZA977666B/en
unknown

1997-08-27
BR
BRPI9704529-2A
patent/BR9704529B1/en
not_active
IP Right Cessation

1997-08-27
JP
JP23137997A
patent/JP3832939B2/en
not_active
Expired – Lifetime

1997-08-29
KR
KR1019970042557A
patent/KR100349424B1/en
not_active
IP Right Cessation

1997-08-29
CN
CN97117915A
patent/CN1100528C/en
not_active
Expired – Lifetime

1997-08-29
ID
IDP973024A
patent/ID18151A/en
unknown

1997-08-29
AR
ARP970103947A
patent/AR008833A1/en
active
IP Right Grant

1997-09-26
TW
TW086114077A
patent/TW431890B/en
not_active
IP Right Cessation

1998

1998-01-22
US
US08/911,301
patent/US5989572A/en
not_active
Expired – Lifetime

Patent Citations (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5587149A
(en)

1995-02-06
1996-12-24
R.P. Scherer Corporation
Topical application emulsions

Also Published As

Publication number
Publication date

KR19980019155A
(en)

1998-06-05

KR100349424B1
(en)

2002-11-18

US5989572A
(en)

1999-11-23

IN189566B
(en)

2003-03-29

ZA977666B
(en)

1999-02-26

EP0826366B1
(en)

2003-10-29

AU3416397A
(en)

1998-03-05

CN1100528C
(en)

2003-02-05

DE69725804T2
(en)

2004-08-12

TW431890B
(en)

2001-05-01

NZ328512A
(en)

1998-07-28

ID18151A
(en)

1998-03-05

JPH1087476A
(en)

1998-04-07

AR008833A1
(en)

2000-02-23

ES2210460T3
(en)

2004-07-01

CA2212850C
(en)

2005-11-08

EP0826366A2
(en)

1998-03-04

US5690947A
(en)

1997-11-25

BR9704529A
(en)

1998-10-27

JP3832939B2
(en)

2006-10-11

BR9704529B1
(en)

2008-11-18

CN1176783A
(en)

1998-03-25

EP0826366A3
(en)

1998-04-15

CA2212850A1
(en)

1998-02-28

DE69725804D1
(en)

2003-12-04

Información de contacto